Get the Daily Brief
Latest Biotech News
Oral Microbiome Species Linked to Elevated Pancreatic Cancer Risk
A large study led by NYU Langone Health identified a set of 27 bacterial and fungal oral species associated with a 3.5-fold increased risk of pancreatic cancer. Using metagenomic sequencing of...
Luxa Biotechnology Reports Vision Gains in Dry AMD Stem Cell Trial
Luxa Biotechnology published Phase 1/2a clinical trial data showing promising safety and efficacy of its adult retinal pigment epithelial stem cell (RPESC-RPE) transplantation in dry age-related...
Emerging AI Tool Forecasts Development of Over 1,200 Diseases Up to 20 Years Ahead
Researchers have developed Delphi-2M, an artificial intelligence model that integrates electronic health records and lifestyle data to predict individual risks for more than 1,200 diseases decades...
Advanced CRISPR Activation Restores Gene Expression in SCN2A Neurodevelopmental Disorder Model
Scientists at the University of California, San Francisco demonstrated that CRISPR activation technology can upregulate the functional SCN2A gene copy in mice with haploinsufficiency, a condition...
Cellares Unveils Automated Cell Therapy QC Platform with Strategic Partnerships
Cellares introduced the Cell Q, an automated quality control platform designed to match commercial-scale throughput demands in cell therapy manufacturing. The system integrates advanced...
Immunotherapy Advances in Hematology: Regeneron’s Lynozyfic Shows 100% Response in Smoldering Myeloma
Regeneron reported compelling early results for Lynozyfic, a T cell engager therapy, achieving complete response in all participants in a small study for smoldering multiple myeloma, a precursor...
FDA Approves Subcutaneous Keytruda: Merck's Bid to Extend Blockbuster Life
Merck secured FDA approval for a subcutaneous formulation of Keytruda, the company's leading cancer immunotherapy drug. This new delivery method is designed to improve patient convenience while...
Roche Acquires 89bio for $2.4 Billion to Target MASH Liver Disease
Roche announced the acquisition of biotech firm 89bio in a deal valued up to $3.5 billion, including upfront and milestone payments. The deal centers on 89bio's lead asset pegozafermin, an...
CRISPR-Based Tuberculosis Test Advances Community Screening in Low-Resource Settings
Researchers from Tulane University and Shenzhen Third People's Hospital have developed ActCRISPR-TB, a CRISPR-Cas12a-based tuberculosis diagnostic test optimized for non-sputum samples such as...
Dualitas Therapeutics Raises $65 Million to Advance Bispecific Drugs for Autoimmune Diseases
Dualitas Therapeutics closed a $65 million Series A funding round to develop bispecific antibodies targeting two receptors on the same immune cell for enhanced immunomodulation in autoimmune and...
FDA Approves Stealth’s Barth Syndrome Therapy: First Mitochondria-Targeted Treatment
The FDA granted approval to Stealth BioTherapeutics’ Barth syndrome therapy, marking the first mitochondria-targeted treatment for this rare genetic disorder. This regulatory milestone offers a...
AI Model Predicts Risk of Over 1,000 Diseases Up to 20 Years Ahead
A new generative artificial intelligence model, Delphi-2M, developed using UK Biobank data from over 400,000 participants, can simultaneously forecast the risk and timing of developing 1,258...
Endpoints 11 Highlights: Top Biotech Startups Driving Innovation in 2025
The Endpoints 11 list for 2025 celebrates 11 of the most promising biotech startups poised to shape the industry's future. Companies include Chai Discovery focusing on AI-driven drug design, Umoja...
CHMP Recommends, FDA Approves Subcutaneous MAbs Including Keytruda and Lunsumio
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval and the FDA has approved subcutaneous formulations of key monoclonal antibodies...
ACIP Vaccine Deliberations Stir Public Health Debate on Immunization Schedules
The U.S. CDC's Advisory Committee on Immunization Practices (ACIP) underwent contentious discussions regarding the recommendation to delay the hepatitis B birth dose in certain newborns and to...
FDA Approves Subcutaneous Keytruda Amid Competitive Immuno-Oncology Market
The U.S. Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Keytruda, Merck's leading cancer immunotherapy drug. The approval seeks to provide a less invasive...
Roche Acquires 89bio to Bolster MASH Drug Portfolio with Pegozafermin
Swiss pharmaceutical giant Roche has agreed to acquire biotech firm 89bio for up to $3.5 billion, securing access to its late-stage fibroblast growth factor 21 (FGF21) analogue, pegozafermin. This...
CRISPR-Based Tuberculosis Test Offers Affordable, Non-Sputum Screening in Low-Resource Settings
Researchers led by Tulane University and Shenzhen Third People's Hospital have developed an enhanced CRISPR-based diagnostic assay, ActCRISPR-TB, designed for rapid, affordable tuberculosis (TB)...
Biotech Venture Firm T.Rx Capital Launches With $77.5 Million, Led by Robert Langer’s Son
T.Rx Capital, a newly established life sciences venture capital firm co-founded by Michael Langer, son of biotech legend Robert Langer, has closed a $77.5 million inaugural fund. The firm aims to...
AI Deep Learning Model Predicts Risk for Over 1,000 Diseases Decades in Advance
Scientists have developed a novel artificial intelligence (AI) model named Delphi-2M that simultaneously forecasts an individual's risk of developing more than 1,000 diseases with up to 20 years...